Potensi Nanopartikel Kitosan Sebagai Agen Penghantaran Kandidat Vaksin DNA Hepatitis B (pEGFP-C1-HBcAg) Pada Sel HeLa
Maulana Ikhsan, Dr. drh. Asmarani Kusumawati, M.P. ; Dr. Dini Wahyu Kartika Sari, S.Pi., M.Si.
2024 | Tesis | S2 Bioteknologi
Hepatitis B virus (HBV) can cause acute to chronic infections. This virus is one of the main pathogens that cause hepatitis, cirrhosis, and hepatocellular carcinoma. Vaccination is the best solution for the prevention of Hepatitis B. Although recombinant DNA vaccines are available, when vaccination is carried out, the immunogenicity produced is weak or insufficient when given without a delivery agent. Drug delivery agents or vaccines have an important role in improving the efficacy and safety of medical therapies. These delivery agents are designed to optimize the bioavailability, stability, and timely release of drugs or antigens into the body. This study aims to prepare a Hepatitis DNA vaccine (pEGFP-C1-HBcAg) with chitosan as a delivery agent. The chitosan-pEGFP-C1-HBcAg nanoparticle complex in this study was prepared by the coacervation complex method. The methods in this study are recombinant DNA plasmid transformation and recombinant cloning, recombinant DNA plasmid isolation, plasmid restriction, plasmid PCR, chitosan-pEGFP-C1-HBcAg nanoparticle complex formulation, nanoparticle complex characterization, cytotoxic test, HeLa cell culture transfection and fluorescence observation. The results of the chitosan-pEGFP-C1-HBcAg nanoparticle complex with a ratio of 1:0.4 (1000 ng: 400 ng) has an average size of 138.9 nm and a zeta potential of -13.6 mV. Cytotoxicity test showed 80-90% compared to untreated cells as a negative control. EGFP expression after transfection was confirmed by microscopic examination and showed green fluorescence, so it can be concluded that chitosan nanoparticles have good potential as a carrier agent for pEGFP-C1-HBcAg.
Keywords: HBV, DNA vaccine, Chitosan, HeLa cell Line.
Kata Kunci : Hepatitis B, vaksin DNA, kitosan, HeLa